{
}
In January, Saudi Arabia's Public Investment Fund (PIF) issued a US dollar bond, sold Thiqah Business Services for $907 million, and acquired a 23% stake in Saudi Re. The fund also invested $200 million in the SPDR Saudi bond ETF to enhance the Kingdom's debt market. PIF's activities in 2025 included acquiring Niantic’s gaming division for $3.5 billion and reaffirming its commitment to Newcastle United FC. The tourism sector saw a surge in private investment, reaching SR14.2 billion, with 40% from foreign investors, as the Kingdom aims to generate $80 billion by 2030 to diversify its economy. PIF ranked as the second most active sovereign investor globally in February, committing $3 billion across 22 deals, reflecting its strategic shift towards long-term resilience in sectors like healthcare and electric vehicles.
OLD Second National Bank of Aurora increased its stake in Regeneron Pharmaceuticals by 0.5%, now holding 2,843 shares valued at $2,025,000. Other institutional investors, including Rakuten Securities and TD Private Client Wealth, also raised their positions significantly in the fourth quarter. Regeneron’s stock has seen price target adjustments from various analysts, with an average rating of "Moderate Buy" and a current price of $634.99, reflecting a market cap of $69.42 billion.
Saudi Arabia’s Public Investment Fund (PIF) ranked as the world’s second most active sovereign investor in February, committing $3 billion across three overseas deals. This surge reflects a strategic shift towards global opportunities, with PIF managing $925 billion in assets and focusing on sectors like healthcare and gaming. Notable moves include increased stakes in Lucid Motors and Amazon, alongside a $3.5 billion acquisition of Niantic’s gaming division.
Regeneron Pharmaceuticals, Inc. has 83.31% of its stock owned by institutional investors and hedge funds. The company, known for its treatments like EYLEA, has recently faced downgrades from analysts, with UBS lowering its rating to "neutral" and adjusting the price target to $738.00, indicating a potential upside of 4.91%. Despite a "Moderate Buy" rating overall, several analysts have set lower price targets, reflecting a cautious outlook on the stock's performance.
Regeneron Pharmaceuticals, Inc. focuses on developing and selling drugs for eye and inflammatory diseases and cancer. Its net sales are primarily derived from product sales (56.6%) and collaboration agreements (40.4%), with significant partnerships with Sanofi, Bayer, and Roche. The company has around 35 products in clinical development as of the end of 2022.
Roche is projected to lead the pharmaceutical industry in sales by 2025, despite not having any products in the top drug rankings. Eli Lilly and Novo Nordisk are expected to rise in the rankings, with combined sales from their GLP-1 drugs surpassing $70 billion this year. Meanwhile, Pfizer is anticipated to drop from fifth to ninth place, while Merck & Co. and AbbVie are expected to secure the second and third spots, respectively.
Intellia Therapeutics, Inc. has seen its shares plummet 60.4% in 2024, significantly underperforming the industry and the S&P 500. Despite promising data from its CRISPR-based therapies, including the investigational nexiguran ziclumeran for ATTR amyloidosis, investor disappointment has grown due to recent trial results. The company continues to advance its innovative gene editing pipeline, with ongoing studies showing substantial serum TTR reduction in patients.
The Global Uveitis Treatment market is projected to grow from USD 725 million in 2024 to USD 1.28 billion by 2032, with a CAGR of 8.5%. The study covers various treatment types, including corticosteroids and biologic agents, and offers customization options for regional and application-specific analysis. Key players include Novartis, Pfizer, and AbbVie, with North America leading the market and Asia-Pacific identified as the fastest-growing region.
Regeneron's Eylea HD has demonstrated noninferior visual acuity gains compared to the original Eylea in patients with macular edema following retinal vein occlusion, paving the way for a 2025 FDA filing. The drug, which generated $392 million in U.S. sales in Q3, faces competition from Amgen's biosimilar and Roche's Vabysmo, but its potential approval in RVO could boost sales further.
Roche has received EU approval for a prefilled syringe (PFS) of its ophthalmology drug Vabysmo, designed to treat neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. This PFS offers a convenient administration method for over 9 million affected individuals in the EU and is the first of its kind containing a bispecific antibody for these conditions. Following strong sales growth, the approval is expected to further enhance Roche's revenue amid increasing competition in the ophthalmology market.
Regeneron Pharmaceuticals, Inc.
Companies
| Symbol | REGN |
| Name | Regeneron Pharmaceuticals, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | NY |
| City | Tarrytown |
| Zipcode | 10591-6707 |
| Website | http://www.regeneron.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
saudi arabia's tourism sector attracts record investment amid shifting travel trends
United States Dollar
Regeneron Pharmaceuticals, Inc.
Amazon.com, Inc.
Thermo Fisher Scientific Inc.
SAU
Mohammed bin Salman Al Saud
Ahmed Al Khateeb
Show more
12:54 02.04.2025
regeneron pharmaceuticals sees mixed analyst ratings and institutional investment growth
16:56 01.04.2025
saudi public investment fund ranks second in global sovereign investment activity
United States Dollar
British Pound Sterling
Regeneron Pharmaceuticals, Inc.
Amazon.com, Inc.
Thermo Fisher Scientific Inc.
KOR
SAU
GBR
CAN
Mohammed bin Salman Al Saud
Show more
14:12 25.03.2025
regeneron pharmaceuticals faces downgrades as analysts adjust price targets
14:17 16.01.2025
regeneron pharmaceuticals faces downgrade as it focuses on diverse drug portfolio
13:02 16.01.2025
roche set to lead global pharma sales in 2025 as rivals rise
United States Dollar
Merck & Co., Inc.
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
ABBVIE
Pfizer Inc.
Novartis AG
Sanofi
AstraZeneca PLC
Gilead Sciences, Inc.
GSK plc
Eli Lilly and Co
Johnson & Johnson
Novo Nordisk A/S
Robert F. Kennedy Jr.
Show more
19:07 03.01.2025
Intellia Therapeutics stock plummets amid disappointing therapy data and performance
18:57 20.12.2024
global uveitis treatment market poised for significant growth by 2032
Pfizer Inc.
Bayer AG
Novartis AG
Regeneron Pharmaceuticals, Inc.
Merck & Co., Inc.
CIPLA LTD
Lupin Limited
Hoffmann-La Roche AG
Bausch Health Companies Inc.
BIOGEN
ABBVIE
Alimera Sciences Inc.
SAU
ISR
FRA
RUS
DEU
TWN
ARG
ARE
AUT
TUR
SGP
NZL
CHL
USA
BRA
CAN
ITA
JPN
IDN
GBR
ESP
IND
MYS
COL
AUS
THA
EGY
VNM
KOR
PHL
CHN
ZAF
MEX
Nidhi Bhavsar
Show more
20:41 19.12.2024
Regeneron advances Eylea HD for retinal vein occlusion amid rising competition
United States Dollar
Bayer AG
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
Amgen Inc.
USA
George Yancopoulos
Show more
14:20 18.12.2024
Roche secures EU approval for Vabysmo prefilled syringe for retinal diseases
Swiss Franc
Bristol-Myers Squibb Co
Regeneron Pharmaceuticals, Inc.
Hoffmann-La Roche AG
Gilead Sciences, Inc.
CHE
Show more
19:40 16.12.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Banking Regulations
Domestic Politics
Global Financial Events
Retail and Consumer Goods
CEO Changes
Government Policies
Global Trade Developments
Workplace Trends
Startups & Entrepreneurship
Market Analysis and Predictions
Elections & Campaigns
Central Bank Actions
Government Economic Policies
Supply Chain Management
Hedge Funds & Private Equity
Countries:
Companies:
Tesla, Inc.
UniCredit S.p.A.
Apple Inc.
Banco BPM S.p.A.
Deutsche Bank Money Market PP
JPMorgan Chase & Co.
Barclays PLC
Credit Suisse Strategic Income I
CREDIT AGRICOLE
SpaceXCoin USD
Amazon.com, Inc.
The Goldman Sachs Group, Inc.
Lloyds Banking Group plc
BNP Paribas SA
UBS Group AG
Credit Agricole
Banco Santander, S.A.
Reinsurance Group of America, Incorporated
Google Inc.
Berkshire Hathaway Inc.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Japanese Yen
Indian Rupee
South Korean Won
Hong Kong Dollar
Canadian Dollar
Offshore Chinese Yuan
Australian Dollar
Singapore Dollar
Norwegian Krone
Filipino Peso
Mexican Peso
Indonesian Rupiah
Vietnamese Đồng
Thai Baht
Danish Krone
People: